Drug intelligence / Profile preview

PT950

Development stage: Preclinical
Lead developer: Phanes Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PT950 is a conditional T-cell engager (TCE) bispecific antibody developed by Phanes Therapeutics for the treatment of ovarian cancer. The molecule is designed to simultaneously target a tumor-associated antigen (TAA) expressed on malignant cells and the CD3 complex on T cells. The "conditional" nature of the antibody is engineered to ensure that T-cell activation occurs preferentially within the tumor microenvironment, which is intended to minimize systemic immune activation and improve the safety profile compared to traditional T-cell engagers. As of August 2025, PT950 is in the IND-enabling stage of development.

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on PT950.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PT950.

Explore the full profile